Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Differential EphA2 epitope display on normal versus malignant cells.

Karen T Coffman1, Min Hu, Kelly Carles-Kinch

  • 1MedImmune, Inc., 35 West Watkins Mill Road, Gaithersburg, MD 20878, USA.

Cancer Research
|November 25, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2025 In Review: Trends in Pharmaceutical Innovation.

Drug discovery today·2026
Same author

Geopolitical contributions to pharmaceutical innovation.

Drug discovery today·2025
Same author

Ignore at Your Own Risk: American Academic Contributions to the Development of Small Molecule Therapeutics.

Drug discovery today·2025
Same author

Target & Mechanism Selection in Pharmaceutical Innovation: A Source for Concern or Optimism?

Drug discovery today·2025
Same author

2024 in Review: FDA Approval of New Medicines.

Drug discovery today·2025
Same author

Antibiotic Development: Lessons from the Past and Future Opportunities.

Pharmaceutical research·2024

Targeting the EphA2 receptor tyrosine kinase with specific antibodies shows promise for cancer therapy. These antibodies selectively bind cancer cells, inhibiting tumor growth by inducing EphA2 degradation and minimizing toxicity to normal cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • The EphA2 receptor tyrosine kinase is overexpressed in many human cancers, acting as an oncoprotein.
  • Altered EphA2 localization and function in cancer are linked to unstable cell-cell contacts, hindering ligand binding.
  • EphA2 ligand binding normally inhibits tumor growth and invasiveness and induces EphA2 degradation.

Purpose of the Study:

  • To investigate the therapeutic potential of targeting EphA2 with agonistic antibodies.
  • To determine if EphA2 antibodies can selectively bind to malignant cells.
  • To elucidate the mechanism of antibody action in reducing tumor growth.

Main Methods:

  • Utilized a subset of agonistic EphA2 antibodies.
  • Assessed antibody binding to malignant versus non-transformed epithelial cells.

Related Experiment Videos

  • Investigated the role of cell-cell adhesions in epitope availability.
  • Evaluated antibody efficacy in xenograft tumor models.
  • Analyzed EphA2 protein degradation as a mechanism of action.

    • Main Results:

    • A subset of agonistic EphA2 antibodies selectively binds epitopes on malignant cells, not normal cells.
    • Differential cell-cell adhesions in cancer create accessible EphA2 binding sites.
    • Stable intercellular junctions in normal cells occlude antibody and ligand binding sites.
    • Antibody targeting of EphA2 reduced tumor growth in xenograft models.
    • Antibody-mediated EphA2 protein degradation was identified as the mechanism of action in vivo.

    Conclusions:

    • Agonistic EphA2 antibodies offer a targeted therapeutic strategy for EphA2-expressing cancers.
    • Selective binding to malignant cells minimizes potential toxicities to normal tissues.
    • EphA2 antibody therapy holds promise for reducing tumor growth and invasiveness.
    • Induction of EphA2 degradation is a key mechanism for therapeutic benefit.